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Jones et al. (2010) propose an innovative strategy for the development of bioactive cell-penetrating peptides.
They combine computer-based designwith specific targeting to elaborate a potent cell-penetrating bioactive
peptide derived from cytochrome C. This short chimera peptide induces tumor cell apoptosis by targeting
and sequestering nucleoporin, a key component of the nuclear pore complex.Cell proliferation and programmed cell
death are controlled by a network of
both posttranslational protein modifica-
tions and protein/protein interactions,
which are essential tomaintain the spatio-
temporal activation of the different path-
ways within the cell. Although small mole-
cules remain the major drugs used in
clinic, in numerous cases their therapeutic
impact has reached limitations due to
their insufficient capability to reach
targets, lack of specificity, requirement
for high doses leading to toxicity, and
major side effects (Utreja et al., 2010).
Therefore, targeting protein/protein inter-
faces involved in the development of
pathologies has been proposed as a
potent strategy to overcome these limita-
tions and the lack of specificity of the
currently used therapeutic molecules.
Several small peptides have been de-
scribed to block protein/protein interac-
tions in vitro and in cellulo and to modu-
late cell cycle aberrant proliferation,
apoptosis, and viral infection (Agopian
et al., 2009; Rizzolio et al., 2010). The
use of large therapeutic molecules such
as peptides offers several advantages,
including specificity, high potency, and
large contact interfaces with their target,
thereby limiting the emergence of drug
resistance and improving important flexi-
bility for sequence optimization and
stabilization. But in counterpart, the phar-
maceutical potency of these molecules
remains restricted by their low bioavail-
ability in vivo and by their poor cellular
uptake, making the issue of delivery a
keystone for their therapeutic develop-
ment.
Several nonviral technologies have
been designed to improve cellular uptakeof therapeutic molecules. Twenty years
ago, the concept of protein transduction
domain (PTD) or cell-penetrating peptide
(CPP) was proposed based on the obser-
vation that some proteins, mainly tran-
scription factors, shuttle within cells and
from one cell to another (Heitz et al.,
2009). CPPs constitute very promising
tools for noninvasive cellular import of
cargos and have been successfully
applied for ex vivo and in vivo delivery of
a large set of therapeutic molecules,
varying from small chemical molecules,
nucleic acids, proteins, peptides, lipo-
somes, and nanoparticles. CPPs are
either chemically linked to the peptide
drug or form stable, noncovalent com-
plexes with cargos for cellular internaliza-
tion (Heitz et al., 2009). CPPs have
successfully delivered peptides, anti-
bodies, and proteins to target different
diseases, including cancer, asthma, apo-
ptosis, ischemia, and stimulating cyto-
toxic immunity and diabetes in cellulo
and in vivo at the laboratory level as well
as in clinical trials (Wadia and Dowdy,
2005; Heitz et al., 2009).
Although the low potency of peptide
drugs to enter cells has been partially
solved by the use of CPPs, the complexity
remains once additional sequences are
required to control cellular trafficking and
targeting. Moreover, limitations can also
arise from the risk of introducing an exog-
enous carrier peptide sequence in the
cells. Therefore, defining peptides that
can enter the cell, specifically access
a cellular target, and induce a strong bio-
logical response specific for targeted cells
will be a major impact for therapeutic
application of peptide drugs. The combi-
nation of structural and biophysical inves-Chemistry & Biology 17, July 30, 2010tigations together with cell biology studies
has revealed that the size, the net charge,
and structural versatility of CPPs consti-
tute critical parameters to take into
account for their potency and cellular
uptake. Recent development in com-
puter-based design and molecular
modeling of peptides have identified
several common features and provided
new perspectives for in silico and de
novo design of CPPs (Thomas et al.,
2006; Hallbrink et al., 2005). Hallbrink
et al. (2005) have proposed a Quantitative
Structure Activity Relationship (QSAR)-
algorithm based on a series of well-known
CPPs as a means of predicting directly
from the primary sequence of either
natural proteins or artificial peptides, poly-
cationic cell-penetrating peptidemotifs. In
this issue of Chemistry & Biology, QSAR-
algorithm was successfully applied by
Jones et al. (2010) in order to elaborate
bioactive cell permeable peptides that
mimic the role of cytochrome C a key
regulator protein in programmed cell
death (Yamaguchi and Perkins, 2009).
Using human Cytochrome C as a protein
template, 31 potential CPPs were identi-
fied, all derived from helical motifs and
mainly the helix at the C terminus of
the cytochrome C, which constitutes
the most thermodynamically favorable
structure for cell-membrane crossing. A
potent peptide covering residues 77-101
Cyt77-101 has been reported to efficiently
enter the cell and to mimic the apopto-
genic activity of native human cytochrome
C by inducing moderate apoptosis.
Quite often, the low ratio between
cellular uptake and the corresponding
biological response is directly linked to
the low potency of the peptide to escapeª2010 Elsevier Ltd All rights reserved 679
Figure 1. Design and Potency of Bioactive Cell-Penetrating
Peptides
Cell-penetrating peptide (CPP) can be linked to inhibitor and targeting motif
(TM) or computer-based optimized using (QSAR) (1) to a single sequence con-
taining bioactive cell-penetrating sequence (BCPP) that will improve cellular
uptake (3), endosomal release (4), and biological response (6), and a targeting
motif (TM) that will favor either cell targeting (2) or cellular trafficking (5).
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poor ability to reach the target
within the cell. It is therefore
not only important to increase
selectivity and specificity of
therapeutic molecules, but
also essential to improve their
cellular trafficking to the
target. Jones et al. (2010)
have proposed a chimera
peptide combining the highly
penetrating active peptide
Cyt77-101 together with a
nona-peptide containing the
motif ‘‘FXFG’’ derived from
the C terminus of nucleoporin
153 (Nup153). The goal was
to target the FG-nucleoporin
Nup153, one of the key
players in the control of
nuclear import and the selec-
tivity of the nuclear pore com-
plex NPC (Stewart, 2007).
The Nup153-Cyt-C peptide
exhibits a strong pro-apo-
ptotic activity at submicromo-
lar concentration, which is
about 100 fold higher thanthe parental peptide. From a mechanistic
point of view, although different targets
seem to be involved, Nup153-Cyt C
sequesters Nup153 at the periphery of
the nuclear envelope and significantly
disorganizes nuclear pore component
architecture, thereby triggering apo-
ptosis. The presence of Nup153 targeting
sequence not only increases the peptide
efficiency, but also its cellular uptake
and endosomal release, which is due to680 Chemistry & Biology 17, July 30, 2010 ª2an increase in the cationic and aromatic
character of the peptide.
Jones et al. (2010) describe a very
promising strategy for identification of
potent protein/protein interface cell-
penetrating peptide inhibitors (Figure 1).
Applying this strategy to computer-based
design of mimics of cytochome C, they
have identified a potent peptide drug
and suggest that nuclear pore organiza-
tion constitutes an interesting new target010 Elsevier Ltd All rights reservedfor induction of apoptosis.
Having only one peptide se-
quence that can inhibit a spe-
cific cellular pathway, enter
cells, and be further modified
for in vivo targeting will open
new perspectives for the clin-
ical application of peptides.REFERENCES
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